Top

Osteoporosis International

Published in:

01-02-2007 | Original Article

Adherence of academic geriatric practitioners to osteoporosis screening guidelines

Authors: D. N. McNally, A. M. Kenny, J.-A. Smith

Published in: Osteoporosis International | Issue 2/2007

Abstract

Objectives

To examine the bone mineral density (BMD) testing habits of geriatricians and geriatric fellows at the University of Connecticut fellowship training program to evaluate their adherence screening guidelines.

Design

Retrospective chart review.

Setting

University based academic geriatric practice in Farmington, CT.

Participants

Chart review of two hundred female patients over age 65 under care of seven faculty geriatricians and eight geriatric fellows in training.

Measurements

Data collected included BMD testing status, patient’s osteoporosis risk factors and functional status.

Results

Physicians ordered BMD tests in 151 (76%) patients; 128 (64%) had a bone mineral density test within three years. A personal history of fracture was the only osteoporosis risk factor that correlated to higher rates of osteoporosis testing. Physicians were more likely to order BMD screening in younger patients (92% in 65–74 vs. 74% in ages 85+, P=.031), patients independent in activities of daily living (72% vs. 32, P=.002), and patients without dementia (70% vs.37%, p=.007). BMD testing results found 82% with osteopenia or osteoporosis.

Conclusions

A geriatric group that is highly attuned to bone health demonstrated more optimal adherence to OP testing guidelines for all “at-risk” older women and better than reported previously. Functional status more strongly predicted BMD testing than osteoporosis risk factors. This study suggests that with improved physician education and familiarity with the disease, high rates of BMD testing for earlier identification of geriatric patients at risk for osteoporosis are achievable.

Melton LJ, Lane AW, Cooper C, Eastell R, O’Fallon WM, Riggs BL (1993) “Prevalence and incidence of vertebral deformities.” Osteoporosis Int 3:113–119CrossRef

Burger H, Van Daele PL, Grashuis K, Hofman A, Grobbee DE, Schutte HE, Birkenhager JC, Pols HA (1997) “Vertebral deformities and functional impairment in men and women.” JBMR 12:152–157

Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) “Ten year probabilities of osteoporotic fracture according to BMD and diagnostic thresholds.” Osteoporosis Int 12:989–995CrossRef

Fulton JP (1999) “New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation.” Med Health 82:110

National Osteoporosis Foundation. “Physician’s guide to prevention and treatment of osteoporosis.” (Washington, DC) 2003

“Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.” World Health Organization. WHO Technical Report Series 843. (Geneva) 1994

Kern LM, Powe NR, Levine MA, Fitzpatrick AL, Harris TB, Robbins J, Fried LP et al (2005) “Association between screening for osteoporosis and the incidence of hip fracture.” Ann Intern Med 142:173–181PubMed

Cummings SR, Black DM, Thompson DE et al (1998) “Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.” JAMA 280:2077–2082PubMedCrossRef

Reginster J, Minne HW, Sorensen OH et al (2000) “Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. (VERT) Study Group.” Osteoporosis Int 11:83–91CrossRef

10.

Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D et al (2000) “A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.” Am J Med 109:267–276PubMedCrossRef

11.

Delmas PD, Bjarnason NH, Mitlak BH et al (1997) “Effects of Raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.” N Engl J Med 337:1641–1647PubMedCrossRef

12.

Neer RM, Arnaud CD, Zanchetta JR et al (2001) “Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis.” N Engl J Med 344:1434–1441PubMedCrossRef

13.

Lewiecki EM, Watts NB, McClung MR et al (2004) “Official positions of the International Society for Clinical Densitometry.” J Clin Endocrinol Metab 89:3651–3655PubMedCrossRef

14.

US Preventive Services Task Force (2002) “Screening for osteoporosis in postmenopausal women: recommendations and rationale.” Ann Intern Med 137:526–528

15.

“Bone Health and Osteoporosis: A Report of the Surgeon General.” (2004) Available online http://www.surgeongeneral.gov/library/bonehealth Accessed Dec. 11, 2005

16.

Siris ES, Miller PD, Barrett-Connor E et al (2001) “Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.” JAMA 286:2815–2822PubMedCrossRef

17.

Solomon DH, Connelly MT, Rosen CJ et al (2003) “Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England.” Osteoporosis Int 14:123–129

18.

Sheehan J, Mohamed F, Reilly M et al (2000) “Secondary prevention following fractured neck of femur: a survey of orthopaedic surgeons practice.” Ir Med J 93:105–107PubMed

19.

Hajcsar EE, Hawker G, Bogoch ER (2000) “Investigation and treatment of osteoporosis in patients with fragility fractures.” Can Med Assoc J 163:819–822

20.

Solomon DH, Brookhart MA, Gandhi TK et al (2004) “Adherence with osteoporosis practice guidelines: A multilevel analysis of patient, physician, and practice setting characteristics.” Am J Med 117:919–924PubMedCrossRef

21.

Morris CA, Cabral D, Cheng H et al (2004) “Patterns of bone mineral density testing: current guidelines, testing rates, and interventions.” J Gen Intern Med 19:810–811CrossRef

22.

Cummings SR, Browner WS, Grady D et al (eds) (2001) Designing clinical research: an epidemiologic approach, 2nd ed. Lippincott, Williams & Wilkins. (Philadelphia)

23.

Ingelfinger JH, Ware F, Mosteller LT (1994) Biostatistics in Clinical Medicine (3rd edn) McGraw Hill (New York)

24.

Cassidy LD, Marsh GM, Holleran MK et al (2002) “Methodology to improve data quality from chart review in the managed care setting.” Am J Managed Care 8:787–793

25.

Gilbert EH, Lowenstein SR, Koziol-McLain J et al (1996) “Chart reviews in emergency medicine: Where are the methods?” Annals Emer Med 27:305–308

26.

Peabody JW, Luck J, Glassman P (2000) “Comparison of vignettes, standardized patients and chart abstraction: a prospective validation study of 3 methods for measuring quality.” JAMA 283:1715–1722PubMedCrossRef

27.

Yawn BP, Wollan P (2005) “Interrater reliability: Completing the methods description in medical records review studies.” AM J Epidemiol 161:974–977PubMedCrossRef

28.

Centers for Disease Control and Prevention. Health, United States, (2005) Atlanta (GA): Department of Health and Human Services (US). CDC

29.

Centers for Disease Control and Prevention (2002) Behavioral Risk Factor Surveillance System Survey Data BRFSS. Atlanta (GA): Department of Health and Human Services (US). CDC

30.

Probstfield JL, Weiner DH, Shrikant I et al (1989) The studies of left ventricular dysfunction (SOLVD) experience with a placebo run-in phase. Control Clin Trials 10:334

31.

Brookhart MA, Solomon DH, Wang P et al (2006) “Explained variation in a model of therapeutic decision making is partitioned across patient, physician and clinic factors.” J Clin Epi 59:18–25CrossRef

32.

Breeze E, Clarke R, Shipley MJ et al (2006) Cause-specific mortality in old age in relation to body mass index in middle age and old age: follow up of the Whitehall cohort of male civil servants. Int J Epidemiol 35169–178PubMedCrossRef

33.

Sergi G, Perissinotto E, Pisent C et al (2005) ILSA Working Group. An adequate threshold for body mass index to detect underweight condidtion in elderly persons: the Italian Longitudinal Study on Aging (ILSA). J Gerontol Biol Sci Med 60:866–871

34.

Sato Y, Kanoko T, Satoh K (2005) “The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial.” Arch Intern Med 165:1737–1742

35.

Levy RL (1985) Social support and compliance: Update. J Hypertens 3:S45–S49

Title: Adherence of academic geriatric practitioners to osteoporosis screening guidelines
Authors: D. N. McNally
A. M. Kenny
J.-A. Smith
Publication date: 01-02-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 2/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0215-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adherence of academic geriatric practitioners to osteoporosis screening guidelines

Abstract

Objectives

Design

Setting

Participants

Measurements

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Design

Setting

Participants

Measurements

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2007

COL1A1, ESR1, VDR and TGFB1 polymorphisms and haplotypes in relation to BMD in Spanish postmenopausal women

The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures

Leptin and bone turnover in monochorionic twins complicated by twin–twin transfusion syndrome

Anti-epileptic medication and bone health

Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu–Cheney syndrome

The importance of communication in secondary fragility fracture treatment and prevention